Wheat ergot fungus-derived and modified drug for inhibition of intracranial aneurysm rupture due to dysfunction of TLR-4 receptor in Alzheimer’s disease

Abstract

Background Alzheimer’s disease (AD) is a form of dementia that strikes elderly people more frequently than it does younger people. The cognitive skills and memory of Alzheimer’s sufferers continue to deteriorate over time. Recent studies have shown that patients with AD have greater amounts of inflammatory markers in their bodies, which suggests that inflammation occurs early on in the progression of the disease. There is a possibility that Aß oligomers and fibrils can be recognised by TLRs, in addition to the microglial receptors CD14, CD36, and CD47. When Aß binds to either CD36 or TLR4, it sets off a chain reaction of inflammatory chemokines and cytokines that ultimately results in neurodegeneration. Diabetes and Alzheimer’s disease have both been recently related to TLR4. The activation of TLR4 has been connected to a variety of clinical difficulties that are associated with diabetes, in addition to the internal environment of the body and the microenvironment of the brain. TLR4 inhibitors have been shown in clinical investigations to not only lessen the likelihood of getting sick but also to increase the average longevity. Result In this work we used molecular docking and molecular dynamics modelling to investigate the effectiveness of FDA-approved antidiabetic plant derived drugs in combating the TLR4 receptor. Molecular docking experiments were used to make a prediction regarding the most important interactions involving 2-Bromoergocryptine Mesylate. With a binding affinity of -8.26 kcal/mol, it stood out from the other candidates as the one with the greatest potential. To verify the interaction pattern that takes place between 2-Bromoergocryptine Mesylate and the TLR4 receptor, a molecular dynamic simulation was run at a time scale of 150 nanoseconds. Because of this, 2-Bromoergocryptine Mesylate was able to make substantial contact with the active site, which led to increased structural stability during the process of the complex’s dynamic development. Conclusion As a result of this, the results of our research may be relevant for future research into the efficacy of 2-bromoergocryptine mesylate as a potential lead treatment for TLR4 receptors in intracranial aneurysm rupture in AD.

Current understanding of macrophages in intracranial aneurysm: relevant etiological manifestations, signaling modulation and therapeutic strategies

“…The Sandip et al. reported that 2-Bromoergocryptine Mesylate is a potential candidate drug to prevent IA rupture by targeting TLR4 receptor ( 129 ). However, as a special agent for targeting TLR4 protein active region in diabetes and Alzheimer’s disease inflammation, 2-Bromoergocryptine Mesylate still has obstacles in broadening pharmacological effects for the IA.…”

Biocide Syntheses Bee Venom-Conjugated ZnO@αFe2O3 Nanoflowers as an Advanced Platform Targeting Multidrug-Resistant Fecal Coliform Bacteria Biofilm Isolated from Treated Wastewater

“…Furthermore, bee venom is an effective antimicrobial [13], anti-inflammatory, anti-apoptosis, anti-fibrosis, and anti-atherosclerosis agent [14,15], as well as an antibacterial agent against a variety of Gram-positive/negative bacteria strains [16][17][18]. Using bee product combinations instead of conventional medication, according to Zambrano et al [19] and Tanu gur and Kekeço glu [20], may have beneficial results.…”